Eli Lilly and Company $LLY Stake Boosted by Factory Mutual Insurance Co.

Key Points

• Factory Mutual Insurance Co. increased its Eli Lilly stake by 5% in the third quarter, adding 4,031 shares to reach 85,031 shares valued at about $98.4 million. Lilly represents 0.9% of the insurer’s portfolio.
• Lilly reported quarterly revenue of $24.4 billion and EPS of $7.48, both above estimates; revenue grew 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, with Mounjaro and Zepbound among its key growth drivers.
• Growth expectations come with risks: the article notes concerns about moderating growth, lower realized drug prices and a high valuation, as well as pipeline setbacks beyond Lilly’s leading GLP-1 products.

Factory Mutual Insurance Co. boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,031 shares of the company's stock after purchasing an additional 4,031 shares during the quarter. Eli Lilly and Company makes up about 0.9% of Factory Mutual Insurance Co.'s investment portfolio, making the stock its 28th largest holding. Factory Mutual Insurance Co.'s holdings in Eli Lilly and Company were worth $98,388,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $13,522,666,000. Jupiter Topco LLC acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $4,667,180,000. Fifth Third Bancorp grew its position in shares of Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock valued at $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Corient Private Wealth LP bought a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $764,116,000. Finally, BlackRock Inc. grew its position in shares of Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,408.68 on Wednesday. The company has a 50-day moving average price of $1,204.03 and a two-hundred day moving average price of $1,095.92. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,449.68. The stock has a market cap of $1.33 trillion, a price-to-earnings ratio of 45.72, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the previous year, the firm posted $7.02 EPS. The firm's quarterly revenue was up 38.6% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 35.61 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio is currently 22.46%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. BMO Capital Markets reiterated an "outperform" rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Scotiabank lifted their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research note on Friday, October 30th. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $1,450.00 target price on shares of Eli Lilly and Company in a report on Monday, October 26th. Royal Bank Of Canada increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an "outperform" rating in a research report on Friday, October 30th. Finally, Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,404.14.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company's stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 18,500 shares of company stock valued at $22,970,770. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.